Prenatal use of newer antiepileptic drugs not associated with increased risk of major birth defects

Use of newer-generation antiepileptic drugs, which are also prescribed for bipolar mood disorders and migraine headaches, during the first trimester of pregnancy was not associated with an increased risk of major birth defects in the first year of life among infants in Denmark, according to a study in the May 18 issue of JAMA. Older-generation antiepileptic drugs are associated with an increased risk of birth defects.

"Epilepsy during is a therapeutic challenge. Since the 1990s, the number of licensed antiepileptic drugs has substantially increased, but safety data on first-trimester use of newer-generation antiepileptic drugs and birth defects are limited," according to background information in the article.

Ditte Molgaard-Nielsen, M.Sc., and Anders Hviid, M.Sc., Dr.Med.Sci., of the Statens Serum Institut, Copenhagen, Denmark, conducted a study to analyze the association between the use of lamotrigine, oxcarbazepine, topiramate, gabapentin, and levetiracetam (newer-generation antiepileptic drugs) during the first trimester of pregnancy and the risk of any major birth defects. The study included data on 837,795 live-born infants in Denmark from January 1996 through September 2008. Individual-level information on dispensed antiepileptic drugs to mothers, birth defect diagnoses, and potential confounders (factors that can influence outcomes) were ascertained from nationwide health registries.

Among the included in the study (837,795), 19,960 were diagnosed with a major birth defect (2.4 percent) during the first year of life. Among 1,532 pregnancies exposed to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam at any time during the first trimester, 49 infants were diagnosed with a major (3.2 percent) compared with 19,911 infants (2.4 percent) among 836,263 unexposed pregnancies. After adjusting for various factors, the authors found that exposure to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam at any time during the first trimester was not associated with an increased risk of major birth defects. Gabapentin and levetiracetam exposure during the first trimester was uncommon.

The prevalence odds ratios for any major birth defects after exposure to any newer-generation antiepileptic drugs during the first trimester were not statistically different for mothers with epilepsy, mood affective disorder or migraine, or without a diagnosis.

"Our study, to our knowledge, is the largest analytic cohort study on this topic and provides comprehensive safety information on a class of drugs commonly used during pregnancy. The use of lamotrigine and oxcarbazepine during the first trimester was not associated with moderate or greater risks of major birth defects like the older-generation , but our study cannot exclude a minor excess in risk of major birth defects or risks of specific birth defects. Topiramate, , and levetiracetam do not appear to be major teratogens [an agent that can cause malformations in an embryo or fetus], but our study cannot exclude minor to moderate risks of major ," the authors conclude.

More information: JAMA. 2011;305[19]1996-2002.

add to favorites email to friend print save as pdf

Related Stories

Epilepsy drug may increase risk of birth defects

Jul 21, 2008

Taking the epilepsy drug topiramate alone or along with other epilepsy drugs during pregnancy may increase the risk of birth defects, according to a study published in the July 22, 2008, issue of Neurology, the medical journa ...

No link between antidepressants and birth defects

May 22, 2008

Expectant mothers can safely use prescribed antidepressants during their first trimester, according to a new study from the Université de Montréal and Ste. Justine Hospital published in the May edition of the British Jo ...

FDA warns of birth defects with Topamax

Mar 04, 2011

(AP) -- The Food and Drug Administration is warning women of child-bearing age that the epilepsy drug Topamax can increase the risk of birth defects around the mouth.

Recommended for you

Study highlights concern for homeless seniors

2 hours ago

A new study for the Greater Victoria Coalition to End Homelessness, co-authored by researchers at the University of Victoria and Simon Fraser University, has found that a disproportionate number of people chronically staying ...

Mateship key to boosting resilient youth

2 hours ago

Having a supportive friend who is connected to their family and greater community can be the critical factor that protects and promotes resilience in vulnerable Aboriginal youth, according to research from ...

Here's to wine, chocolate and a long, healthy life

4 hours ago

Jeanne Calment, who died in 1997 at the age of 122, remains the oldest person on record. One might assume that she led a faultless, healthy lifestyle. Not at all. Every year on her birthday, as her celebri ...

Experts discuss communications gap on vaccines

5 hours ago

The number of parents who refuse to vaccinate their children is on the rise, and with it the incidence of preventable diseases such as measles. The health community could reverse the trend by doing a better ...

User comments